Physician profile
Michael R Gray
NPI 1134277247
$1,351.51
in general payments reported to CMS, 2019-2025
10 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.49 · 2020: $23.13 · 2022: $49.01 · 2023: $462 · 2024: $487 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.23 | 2023-2025 | |
| Bausch Health US, LLC | $259.68 | 2023-2025 | Wellbutrin, Aplenzin |
| Otsuka America Pharmaceutical, INC. | $101.26 | 2019-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $95.78 | 2022-2023 | Qelbree |
| Almatica Pharma LLC | $90.84 | 2025 | Loreev Xr |
| Tris Pharma INC | $54.04 | 2024 | Dyanavel Xr |
| Neos Therapeutics, LP | $38.72 | 2023 | Adzenys Xr-Odt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.13 | 2020 | |
| Theratechnologies INC. | $18.27 | 2025 | Egrifta, Trogarzo |
| Shire North American Group INC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.